Cost-minimization and budget impact analysis of certolizumab pegol for patients with Crohn’s disease, moderate or severe, with relapse after conventional treatment from the perspective of the Brazilian private payer
J. bras. econ. saúde (Impr.); 9 (1), 2017
Objectives: Budget impact and cost-effectiveness analysis are often required by payers when discussing
drug reimbursement. We hereby present a cost-minimization (CMA) and budget impact analysis (BIA) regarding the incorporation of certolizumab pegol (CZP) for the treatment of patients with Crohn’s dise...
